Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial59

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial13

Views

Views
October 20252
November 20252
December 20250
January 20262
February 20260
March 20267
April 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
Brazil3
Spain2
Argentina1
Colombia1
Iran1
Trinidad and Tobago1
Venezuela1
 

Top cities views

Views
San Jose2
Madrid2
Bogotá1
Córdoba1
Gramado1
Jersey City1
Port of Spain1
Taiobeiras1
Valencia1